Peptide data sheet
Wolverine Stack
Recovery
Verdict
unproventhe pairing itself; each component is graded separately below
By MrPepTalks Editorial
Reviewed for scientific accuracy · research information, not medical advice
Last updated Reviewed
Quick answer
"Wolverine stack" is the marketing name for BPC-157 and TB-500 sold together for recovery. Both compounds have been studied almost entirely in animals and cell cultures. Only BPC-157 has a legitimate registered human trial; a public registry search for TB-500 returns no genuine study of the compound at all. Nothing published examines the pairing, so the stack-level verdict is Unproven.
- Class
- Marketed pairing of two research peptides (BPC-157, TB-500)
- Half-life
- Not established; no pharmacokinetic study of the pairing exists
- FDA status
- Not FDA-approved for human use; both components were nominated as bulk substances for pharmacy compounding and both nominations were later withdrawn
- WADA banned?
- Yes
Which form actually works?
BPC-157 on its own
Unproven
A synthetic pentadecapeptide whose published record is dominated by rodent work. A 2025 literature and patent review reports no completed clinical study of efficacy in people, and the safety package is animal toxicology in mice, rats, rabbits and dogs. The public registry carries two entries for the compound: an older Phase 1 safety and pharmacokinetics study in healthy volunteers, and a Phase 2 hamstring-strain trial that began recruiting in 2026, the first registered trial to ask whether the compound changes an injury outcome in people.
TB-500 on its own
Risky
TB-500 is not thymosin beta-4 itself. Analytical work identified the material as the N-terminally acetylated 17-23 fragment, Ac-LKKTETQ. Human trials of thymosin beta-4 have run in heart attack, dry eye and wound care, but those tested the full-length protein rather than this fragment. TB-500 itself has no legitimate registered human trial: the only entry a public registry search returns is one whose own summary declares it a fictional example record, so the genuine count is zero. The 2026 WADA Prohibited List names thymosin-beta4 and its derivatives, TB-500 among them, under section S2.3.
The two together (the stack)
Unproven
No published study, in people or in animals, has examined BPC-157 and TB-500 as a pair, and the public trial registry returns no record of the combination. The synergy sellers describe is an inference from each compound's separate mechanism work. Nobody has run the experiment that would test it.
Third-Party Testing & Certificate of Analysis (COA)
A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.
- HPLC — purity
- High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
- Mass spectrometry (MS) — identity
- Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.
It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.
New to reading one? This guide walks through a COA line by line: how to read a peptide COA.
Sources
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks: the category 2 list and the "nominated but withdrawn" list, which carries entries for BPC-157 and for "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500".
- Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). 2025. PMID 40005999.
- Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID 41490200.
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020. PMID 32334036.
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PMID 22962027.
- Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin beta-4. Front Endocrinol (Lausanne). 2021. PMID 34992578.
- Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules. 2023. PMID 37959764.
- Delcourt V, Garcia P, Chabot B, et al. Equine Doping Controls of Thymosin beta-4: A Population Study and Strategy for Misuse Detection. Drug Test Anal. 2025. PMID 39314109.
- ClinicalTrials.gov NCT07437547. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Sponsor Hudson Biotech; recruiting at Peking University Shenzhen Hospital; study start February 2026.
- ClinicalTrials.gov NCT02637284. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source. Sponsor PharmaCotherapia d.o.o.; study start October 2015; status unknown.
- World Anti-Doping Agency. 2026 Prohibited List, valid 1 January 2026. Section S0 (Non-Approved Substances) names BPC-157; section S2.3 (Growth Factors and Growth Factor Modulators) lists Thymosin-beta4 and its derivatives, e.g. TB-500.
- De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich C. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case. Anal Biochem. 2008. PMID 18342612.